| Name | Title | Contact Details |
|---|
Absorption Systems is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Exton, PA. To find more information about Absorption Systems, please visit www.absorption.com
Reliq Health Technologies is a Vancouver, BC based healthcare technology company that specializes in developing innovative, secure mobile software solutions for the $20 Billion Community Care market. Reliq`s iUGO Health technology platform is a comprehensive hardware and software solution that allows complex patients to receive high quality care in the home, improving health outcomes, enhancing quality of life for patients & families and reducing the cost of care delivery.
Founded in 1950, Miami Children's Hospital is South Florida’s only licensed specialty hospital exclusively for children. The 289-bed hospital is renowned for excellence in all aspects of pediatric medicine with several specialty programs ranked among the best in the nation in 2010 by U.S.News & World Report. The hospital has also been designated an American Nurses Credentialing Center (ANCC) Magnet facility, the nursing profession’s most prestigious institutional honor and is home to the largest pediatric teaching program in the southeastern United States. With a medical staff of more than 650 physicians and over 2,000 employees, the hospital is renowned for excellence in all aspects of pediatric medical care from birth through adolescence, offering more than 40 pediatric specialties and subspecialties, and is home to Florida’s only free-standing pediatric trauma center.
VNA is a New Haven, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
We are a biopharmaceutical company developing first-in-class therapies for cancer. Imetelstat, a novel, first-in-class telomerase inhibitor, is our product candidate in clinical development. Telomerase enables cancer cells to maintain telomere length, which provides them with the capacity for limitless cellular replication. Imetelstat is a potent and specific inhibitor of telomerase. Based on clinical data we obtained in late 2012, we may develop imetelstat to treat one or more hematologic myeloid malignancies such as myelofibrosis, or MF, myelodysplastic syndromes, or acute myelogenous leukemia.